Antagonists of cb1 receptor
US-2022153776-A1 · May 19, 2022 · US
Antagonists of CB1 receptor
US10150793B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10150793-B2 |
| Application number | US-201214118420-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2012 |
| Priority date | May 20, 2011 |
| Publication date | Dec 11, 2018 |
| Grant date | Dec 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pregnenolone derivative wherein said pregnenolone derivative is 17α-Benzyl-3β-fluoropregnenolone, 17α-Benzyl-3β-benzyloxypregnenolone, 3β-Benzyloxy-17α-methylpregnenolone, 17α-Benzylpregnenolone, 3β-Methoxy-17α-methylpregnenolone, 17α-Allyl-3β-methoxypregnenolone or 17α-Benzyl-3β-methoxypregnenolone. 2. A pharmaceutical composition comprising a pregnenolone derivative according to claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10150793B2 cover?
- The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psyc…
- Who is the assignee on this patent?
- Piazza Pier Vincenzo, Vallee Monique, Marsicano Giovanni, and 9 more
- What technology area does this patent fall under?
- Primary CPC classification C07J7/0075. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).